��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Are Untreated MS Patients Representative of Historical Controls or What Do They Say about Trial Recruitment?

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 005

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
Martin Hardmeier, MD	No disclosure on file
	No disclosure on file
Florian Hatz, MD	No disclosure on file
Pedro Martin Souza Fonseca	No disclosure on file
	No disclosure on file
	No disclosure on file
David Leppert, MD (University Hospital Basel)	Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of Geneuro. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Leppert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Leppert has received personal compensation in the range of $0-$499 for serving as a Consultant for Orion. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quanterix. Dr. Leppert has stock in Novartis.
Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel)	Dr. Kappos has nothing to disclose.
Peter Fuhr, MD, FAAN	The institution of Dr. Fuhr has received research support from Roche.